<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455166</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-ARP</org_study_id>
    <nct_id>NCT03455166</nct_id>
  </id_info>
  <brief_title>Identification of New Prognostic Markers in Psoriatic Arthritis</brief_title>
  <official_title>Identification of New Prognostic Markers in Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Galeazzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Galeazzi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of possible markers associated with the onset and / or progression of
      psoriatic arthritis through comparison in patients with psoriasis alone (Ps) and patients
      with psoriasis with joint involvement (PsA), plasma levels of a panel of cytokines referable
      to the Th17 pathway , together with serum levels of MMPs, TIMPs and markers of bone
      remodeling.

      The primary objective of this study is to verify whether the arthropathy component has an
      effect on the metabolic activity of osteoblasts. This will be determined through the study of
      the differences in serum concentrations, between Ps and PsA subjects, of &quot;CTx&quot;, the parameter
      best characterized in terms of analytical variability and intra- and inter-individual
      variability, in the field of bone metabolism.

      The secondary objective is the verification of the differences in serum concentrations of the
      series of parameters specified above, in order to define a complete pattern of variations
      that can identify the molecular pathways involved in the definition of psoriatic arthropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Different markers concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement in serum of: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13, TIMP-1, TIMP-2, TIMP-3, TIMP-4, OPG, RANKL, PINP, CTx-I, DKK1, SOST,IL-1beta, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, INFg, sCD40L, TNFalfa. Correlation with Ps or PsA, and with the severity of the disease</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic arthropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum Markers</intervention_name>
    <description>Serum Markers</description>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_label>Psoriatic arthropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  For Ps group:

        plaque psoriasis no previous treatment with biological drugs

        - For PsA group: plaque psoriasis with arthropathy no previous treatment with biological
        drugs but in treatment as per clinical practice or, alternatively, last treatment with drug
        suspended by a number of days double compared to the half-life of the drug

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Pregnancy

          -  Neoplasia in progress or previous (&lt;5 years)

          -  Other acute or chronic inflammatory diseases

          -  Other rheumatological diseases

          -  Metabolic diseases of the primitive bone

          -  Recent bone fractures (&lt;6 months)

          -  Anxiety, psychosis, depressive disorders

          -  Inability to understand the information provided by the recruiter doctor

          -  For Ps group:

        treatment with biological drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

